<DOC>
	<DOCNO>NCT01996332</DOCNO>
	<brief_summary>This study evaluate efficacy safety oral Tarceva patient advance NSCLC Tarceva monotherapy consider best therapeutic option . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Monotherapy Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient &gt; =18 year age ; locally advance metastatic NSCLC ( Stage IIIB IV ) ; candidate curative surgery radical chemotherapy ; brain metastasis , clinically stable metastasis &gt; =2 month . radiotherapy previous 2 week ; weight loss &gt; 10 % previous 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>